Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Early cessation and non-response are important and possibly related problems in growth hormone therapy: An OZGROW analysis

    Access Status
    Fulltext not available
    Authors
    Hughes, I.
    Choong, C.
    Rath, S.
    Atkinson, Helen
    Cotterill, A.
    Cutfield, W.
    Hofman, P.
    Harris, M.
    Date
    2016
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Hughes, I. and Choong, C. and Rath, S. and Atkinson, H. and Cotterill, A. and Cutfield, W. and Hofman, P. et al. 2016. Early cessation and non-response are important and possibly related problems in growth hormone therapy: An OZGROW analysis. Growth Hormone and IGF Research. 29: pp. 63-70.
    Source Title
    Growth Hormone and IGF Research
    DOI
    10.1016/j.ghir.2016.04.006
    ISSN
    1096-6374
    School
    School of Public Health
    URI
    http://hdl.handle.net/20.500.11937/68051
    Collection
    • Curtin Research Publications
    Abstract

    Objective: To investigate growth hormone (GH) treatment and treatment cessation with respect to efficacy and efficiency. To identify factors that best classify or predict cessation type: completed treatment (CT), early cessation (EC), or non-response (NR). Design: Observational study (1990-2013) of the Australian GH Program comparing CT, EC, and NR groups with respect to demographic, clinical, and response criteria. All patients treated for GH deficiency (GHD; 909), short stature and slow growth (SSSG; 2144), and Turner Syndrome (TS; 626) were included. Information was retrieved from the OZGROW database. Results: 51.9% of patients were EC, 40.7% CT and 7.4% NR.Median treatment durations for NR patients were often longer than patients who completed treatment. EC and NR groups were both associated with poor growth response with males overrepresented.Socioeconomic status differentiated NR (higher) and EC (lower) groups. Conclusions: EC was observed at very high rates and appears, generally, to be a little-recognised but frequent problem in GH therapy.EC and delayed recognition of NR may be interrelated being differentiated by the decision to cease or continue treatment following poor response.Poor treatment compliance is likely a major causal factor in EC.Strategies to address poor response and compliance have been developed, however, given the scale of these problems, it may be that long acting GH formulations or individualized treatment need consideration.

    Related items

    Showing items related by title, author, creator and subject.

    • Smoking cessation: COPD patients' perspective
      Johnson, G.; Kong, D.; Santamaria, Nick; Ioannides-Demos, L.; Stewart, K. (2006)
      Background: Smoking cessation is the most useful and cost effective way to reduce the risk of developing chronic obstructive pulmonary disease (COPD) and stop its progression. Long-term success rates with smoking cessation ...
    • Growth Hormone increases gonadotropin receptors in poor-prognosis patients
      Regan, S.; Stanger, J.; Yovich, J.; Almahbobi, Ghanim (2012)
      Introduction: Growth hormone (GH) exerts multiple functions including its effect on the reproductive system1. We have recently reported that GH supplementation improves implantation and pregnancy rates for poor-prognosis ...
    • Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients
      Lim, Z.; Wong, K.; Olson, H.; Bergin, A.; Downs, Jennepher; Leonard, H. (2017)
      Wiley Periodicals, Inc. © 2017 International League Against Epilepsy Objective: Pathogenic variants involving the CDKL5 gene result in a severe epileptic encephalopathy, often later presenting with features similar to ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.